Condensed Consolidated Statements of Operations and Comprehensive Loss Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 3,063	$ 4,862	$ 8,852	$ 22,266
General and administrative	2,136	2,967	7,265	11,782
Total operating expenses	5,199	7,829	16,117	34,048
Loss from operations	(5,199)	(7,829)	(16,117)	(34,048)
Other income:
(Loss) gain from foreign exchange	(3)	0	(47)	26
Interest and other income (expense), net	(658)	(67)	348	(22)
Other income (expense), net	(661)	(67)	301	4
Net (loss) income	$ (5,860)	$ (7,896)	$ (15,816)	$ (34,044)
Net loss per common stock, basic	$ (0.94)	$ (1.96)	$ (2.51)	$ (8.46)
Net loss per common stock, diluted	$ (0.94)	$ (1.96)	$ (2.51)	$ (8.46)
Weighted-average shares used to compute net (loss) income per share, basic	6,207,638	4,025,489	6,298,846	4,025,489
Weighted-average shares used to compute net (loss) income per share, diluted	6,207,638	4,025,489	6,298,846	4,025,489
Net loss	$ (5,860)	$ (7,896)	$ (15,816)	$ (34,044)
Unrealized (loss) gain on available-for-sale securities	(6)	181	56	(14)
Comprehensive (loss) income	$ (5,854)	$ (7,715)	$ (15,760)	$ (34,030)